Evogene Ltd. Schedules Special Shareholder Meeting for Feb 5, 2025
Ticker: EVGN · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1574565
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
Evogene calling a special shareholder meeting Feb 5th - important votes coming up.
AI Summary
Evogene Ltd. has announced a special general meeting of shareholders scheduled for February 5, 2025, at 3:00 p.m. Israel time. The meeting will be held at Evogene's offices and will include a notice, proxy statement, and proxy card.
Why It Matters
Shareholder meetings are crucial for corporate governance, allowing investors to vote on important matters and influence the company's direction.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding a shareholder meeting and does not contain significant financial or operational news.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- February 5, 2025 (date) — Date of Special General Meeting
FAQ
What is the purpose of the special general meeting of shareholders for Evogene Ltd.?
The filing indicates that the meeting will include a notice, proxy statement, and proxy card, suggesting important resolutions will be presented for shareholder vote.
When and where will the special general meeting of shareholders take place?
The meeting is scheduled for Wednesday, February 5, 2025, at 3:00 p.m. Israel time, at Evogene's offices.
What form does Evogene Ltd. file its annual reports under?
Evogene Ltd. files its annual reports under Form 20-F.
What is the Commission File Number for Evogene Ltd.?
The Commission File Number for Evogene Ltd. is 001-36187.
What is the principal executive office address for Evogene Ltd.?
The principal executive offices are located at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-30 16:01:04
Filing Documents
- zk2432494.htm (6-K) — 14KB
- exhibit_99-1.htm (EX-99.1) — 20KB
- exhibit_99-2.htm (EX-99.2) — 71KB
- exhibit_99-3.htm (EX-99.3) — 15KB
- image0.jpg (GRAPHIC) — 282KB
- image00001.jpg (GRAPHIC) — 266KB
- 0001178913-24-004072.txt ( ) — 875KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Notice, Proxy Statement and Proxy Card for Special General Meeting of Shareholders Evogene Ltd. (" Evogene ") hereby publishes a notice of a special general meeting of shareholders (the " Meeting "), which is scheduled to take place at 3:00 p.m. (Israel time) on Wednesday, February 5, 2025, at Evogene's offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. Shareholders of record at the close of business on Monday, January 6, 2025, are entitled to vote at the Meeting. Attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") is the Notice of Special General Meeting of Shareholders, which contains information concerning the agenda for the Meeting, the required majority for approval of the proposal at the Meeting, the voting procedure and additional general matters related to the Meeting. Attached as Exhibit 99.2 to this Form 6-K is the Proxy Statement for the Meeting, which describes in greater detail the proposal to be presented at the Meeting, including background information related to the proposal, additional logistical information concerning the required vote and means of voting on the proposals, and general information concerning Evogene's board of directors and corporate governance. Attached as Exhibit 99.3 to this Form 6-K is the form of proxy card being distributed by Evogene to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposal to be presented at the Meeting. The contents of Exhibits 99.1, 99.2 and 99.3 to this Form 6-K are incorporated by reference in the registration and 333-259215 ) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibits No. 99.1 Notice for the Special General Meeting of Evogene Ltd. to be held on February 5, 2025 99.2 Proxy Statement for the Special General Meeting of Evogene Ltd. 99.3 Proxy Card to be distributed to record shareholders of Evogene Ltd. to cast their vote at the Special General Meeting of Evogene Ltd. 2 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 30, 2024 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad Yaron Eldad Chief Financial Officer 3